UniQure sells part of Hem­genix roy­al­ty for $400M cash

UniQure sold part of its lu­cra­tive Hem­genix roy­al­ty rights to a pair of in­vest­ment firms for up to $400 mil­lion in cash.

The Dutch biotech said Mon­day that part of its roy­al­ty rights are be­ing sold to Health­Care Roy­al­ty (HCRx) and Sagard Health­care go­ing in­to the next decade. The gene ther­a­py was ap­proved last year as a treat­ment for he­mo­phil­ia B at a list price of $3.5 mil­lion.

The buy­ers will pay uniQure an up­front pay­ment of $375 mil­lion. An ad­di­tion­al $25 mil­lion is on the line, if sales of the gene ther­a­py reach an undis­closed amount in 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER